Thyroid Function in Preterm Infants 27-29 Weeks of Gestational Age During the First Four Months of Life: Results from a Prospective Study Comprising 80 Preterm Infants

Author(s):  
M. Clemente ◽  
P. Ruiz-Cuevas ◽  
A. Carrascosa ◽  
N. Potau ◽  
J. Almar ◽  
...  
Author(s):  
Sabrina Malone Jenkins ◽  
Gary Chan ◽  
Kimberlee Weaver-Lewis ◽  
Tyler Bardsley ◽  
Jace Felix ◽  
...  

2020 ◽  
Vol 8 (2) ◽  
pp. 73-77

Neonatal sepsis is one of the commonest causes of morbidity and mortality in neonates in India compared to the developed countries. Aim: To evaluate the Procalcitonin level this is an early marker in the diagnosis of neonatal sepsis and to assess the suitability of this test in the diagnosis of early-onset sepsis. Method: The prospective study was conducted in the Neonatal Division of Department of Pediatrics, Prathima Institute of Medical Sciences over a period of one year. The blood samples from 100 babies meeting the inclusion and exclusion criteria constituted the material for study. Result: Among the n=100 cases n=39 were procalcitonin positive, compared with gestational age 10 (43.5%) cases were positive with a gestation of <37 weeks and 24 (31.2%) cases positive of cases >37 weeks and there was no statistical significance concerning gestational age the association of material characteristics with procalcitonin positive and CRP positive levels. Blood culture was positive in n=9 (9%) of babies with (90% CI, 5.3-14.9) and negative in n=91 (91%) of babies with (90% CI, 85.2-94.7). Conclusion: A positive blood culture is the only definitive and gold standard for confirming a case of sepsis. Since the culture and sensitivity test requires a minimum period of 48 hours which is a precious time in deciding on the treatment of sepsis in the newborn. Rapid diagnosis by using Procalcitonin and CRP gives a reasonable degree of accuracy in diagnosing neonatal sepsis and will also guide antibiotic therapy. Procalcitonin in comparison with CRP has better sensitivity and hence can detect most cases of neonatal sepsis and better negative predictive value.


2015 ◽  
Vol 14 (3) ◽  
pp. 9-14
Author(s):  
Agnieszka Zubkiewicz-Kucharska ◽  
◽  
Joanna Chrzanowska ◽  
Anna Noczyńska ◽  
◽  
...  

2018 ◽  
Vol 22 (4) ◽  
pp. 602-609 ◽  
Author(s):  
Ilias Chatziioannidis ◽  
Maria Kyriakidou ◽  
Sotiria Exadaktylou ◽  
Evangelia Antoniou ◽  
Dimitrios Zafeiriou ◽  
...  

1987 ◽  
Vol 12 (6) ◽  
pp. 417-420 ◽  
Author(s):  
HENNING LINDEBERG ◽  
JENS U. FELDING ◽  
HELMER SØGAARD ◽  
PETER ILLUM

2018 ◽  
Vol 11 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Z. Khan ◽  
N. Morris ◽  
H. Unterrainer ◽  
N. Haiden ◽  
S.J. Holasek ◽  
...  

2018 ◽  
Vol 27 (1) ◽  
pp. 1-7
Author(s):  
Canan Demir ◽  
Cuneyd Anil ◽  
Yusuf Bozkus ◽  
Umut Mousa ◽  
Altug Kut ◽  
...  

Objective: The objective of this study was to assess the antiproliferative pleiotropic effects of statins on thyroid function, volume, and nodularity. Subjects and Methods: One hundred and six hyperlipidemic patients were included in this prospective study. The 69 patients in the statin groups received atorvastatin (16 received 10 mg and 18 received 20 mg) or rosuvastatin (20 received 10 mg and 15 received 20 mg). The 37 patients in the control group, assessed as not requiring drugs, made only lifestyle changes. Upon admission and after 6 months, all patients were evaluated by ultrasonography as well as for lipid variables (total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides) and thyroid function and structure. Results: After 6 months, no differences in thyroid function, thyroid volume, the number of thyroid nodules, or nodule size were observed in the statin and control groups. In a subgroup analysis, total thyroid volume had decreased more in patients receiving 20 mg of rosuvastatin than that in the control group (p < 0.05). Maximum nodule size had decreased more in those receiving 10 mg of rosuvastatin (p < 0.05). Conclusions: Our results suggest an association between rosuvastatin treatment and smaller thyroid volume and maximum nodule diameter; this could be attributable to the antiproliferative effects of statin therapy on the thyroid.


Sign in / Sign up

Export Citation Format

Share Document